PMID- 38362951
OWN - NLM
STAT- MEDLINE
DCOM- 20240219
LR  - 20240225
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 47
IP  - 2
DP  - 2024 Feb
TI  - Clinical characteristics and statin eligibility of patients under 50 with 
      ST-elevation myocardial infarction.
PG  - e24231
LID - 10.1002/clc.24231 [doi]
LID - e24231
AB  - AIMS: This study seeks to understand the clinical characteristics, risk factors, 
      and statin eligibility of younger adults who present with STEMI. METHODS: We 
      performed a retrospective analysis of a prospective cohort of STEMI patients <50 
      years. Baseline characteristics, medical history, prior medications, drug use, 
      lipid profiles, cardiovascular risk factors were examined. Ten-year ASCVD risk 
      was calculated utilizing the Pooled Cohort Equations. Statin eligibility was 
      determined according to the 2019 American College of Cardiology 
      (ACC)/American Heart Association (AHA) and the 2022 US Preventive Services Task 
      Force (USPSTF) guidelines. RESULTS: Six hundred and thirty-five individuals were 
      included, the majority were men (82.4%) and white (89%), with a median age was 
      46.9 [42.0-48.0]. The most prevalent risk factors were current smoking (59%), 
      hyperlipidemia (44%), and hypertension (37%). Drug use was rare (8.3%). 
      Preventative medication use was low, aspirin was the most common (14%), followed 
      by ACE inhibitors/ARBs (12%), statins (11%), and beta-blockers (9.1%). Mean 
      HDL-C was low at 36.4 +/- 12.0 mg/dL, while mean LDL was unremarkable at 
      112.4 +/- 37.9 mg/dL. According to the 2019 ACC/AHA guidelines, 45.5% were 
      classified as statin recommended, 8.7% were classified as statin considered, and 
      45.8% were classified as statin not recommended. According to the 2022 USPSTF 
      guidelines, 29% were classified as statin recommended, 12.4% were classified as 
      statin considered, and 58.6% were classified as statin not recommended. 
      CONCLUSIONS: Younger adults with STEMI exhibit high rates of tobacco use and low 
      rates of preventative medications use. Approximately half of the cohort did not 
      meet criteria for statin initiation.
CI  - (c) 2024 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
FAU - Haq, Ayman
AU  - Haq A
AUID- ORCID: 0000-0002-7093-420X
AD  - Division of Cardiovascular Medicine, Abbott Northwestern Hospital, Minneapolis, 
      Minnesota, USA.
AD  - Nolan Family Center for Cardiovascular Health, Minneapolis Heart Institute 
      Foundation, Minneapolis, Minnesota, USA.
FAU - Walser-Kuntz, Evan
AU  - Walser-Kuntz E
AD  - Nolan Family Center for Cardiovascular Health, Minneapolis Heart Institute 
      Foundation, Minneapolis, Minnesota, USA.
FAU - Gamam, Abdulrahman
AU  - Gamam A
AD  - Nolan Family Center for Cardiovascular Health, Minneapolis Heart Institute 
      Foundation, Minneapolis, Minnesota, USA.
FAU - Albers, Alexis
AU  - Albers A
AD  - Nolan Family Center for Cardiovascular Health, Minneapolis Heart Institute 
      Foundation, Minneapolis, Minnesota, USA.
FAU - Bae, Aaron
AU  - Bae A
AD  - Nolan Family Center for Cardiovascular Health, Minneapolis Heart Institute 
      Foundation, Minneapolis, Minnesota, USA.
FAU - Benson, Gretchen
AU  - Benson G
AD  - Nolan Family Center for Cardiovascular Health, Minneapolis Heart Institute 
      Foundation, Minneapolis, Minnesota, USA.
FAU - Miedema, Michael D
AU  - Miedema MD
AD  - Division of Cardiovascular Medicine, Abbott Northwestern Hospital, Minneapolis, 
      Minnesota, USA.
AD  - Nolan Family Center for Cardiovascular Health, Minneapolis Heart Institute 
      Foundation, Minneapolis, Minnesota, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
SB  - IM
MH  - Adult
MH  - Male
MH  - United States
MH  - Humans
MH  - Female
MH  - Middle Aged
MH  - *Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
MH  - *ST Elevation Myocardial Infarction/diagnosis/epidemiology/therapy
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Angiotensin Receptor Antagonists/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Risk Factors
MH  - *Cardiovascular Diseases/prevention & control
PMC - PMC10870333
OTO - NOTNLM
OT  - STEMI
OT  - atherosclerotic cardiovascular disease
OT  - primary prevention
OT  - risk stratification
OT  - tobacco
OT  - young adults
COIS- The authors declare no conflict of interest.
EDAT- 2024/02/16 12:46
MHDA- 2024/02/19 06:43
PMCR- 2024/02/16
CRDT- 2024/02/16 08:02
PHST- 2024/01/16 00:00 [revised]
PHST- 2023/10/05 00:00 [received]
PHST- 2024/01/17 00:00 [accepted]
PHST- 2024/02/19 06:43 [medline]
PHST- 2024/02/16 12:46 [pubmed]
PHST- 2024/02/16 08:02 [entrez]
PHST- 2024/02/16 00:00 [pmc-release]
AID - CLC24231 [pii]
AID - 10.1002/clc.24231 [doi]
PST - ppublish
SO  - Clin Cardiol. 2024 Feb;47(2):e24231. doi: 10.1002/clc.24231.